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Abstract
Background:  Two functional single nucleotide polymorphisms (SNPs) in the 5,10-
methylenetetrahydrofolate reductase (MTHFR) gene, C677T and A1298C, lead to decreased
enzyme activity and affect chemosensitivity of tumor cells. We investigated whether these MTHFR
SNPs were associated with breast cancer survival in African-American and Caucasian women.
Methods: African-American (n = 143) and Caucasian (n = 105) women, who had incident breast
cancer with surgery, were recruited between 1993 and 2003 from the greater Baltimore area,
Maryland, USA. Kaplan-Meier survival and multivariate Cox proportional hazards regression
analyses were used to examine the relationship between MTHFR SNPs and disease-specific survival.
Results: We observed opposite effects of the MTHFR polymorphisms A1298C and C677T on
breast cancer survival. Carriers of the variant allele at codon 1298 (A/C or C/C) had reduced
survival when compared to homozygous carriers of the common A allele [Hazard ratio (HR) =
2.05; 95% confidence interval (CI), 1.05–4.00]. In contrast, breast cancer patients with the variant
allele at codon 677 (C/T or T/T) had improved survival, albeit not statistically significant, when
compared to individuals with the common C/C genotype (HR = 0.65; 95% CI, 0.31–1.35). The
effects were stronger in patients with estrogen receptor-negative tumors (HR = 2.70; 95% CI,
1.17–6.23 for A/C or C/C versus A/A at codon 1298; HR = 0.36; 95% CI, 0.12–1.04 for C/T or T/
T versus C/C at codon 677). Interactions between the two MTHFR genotypes and race/ethnicity
on breast cancer survival were also observed (A1298C, pinteraction = 0.088; C677T, pinteraction = 0.026).
Conclusion: We found that the MTHFR SNPs, C677T and A1298C, were associated with breast
cancer survival. The variant alleles had opposite effects on disease outcome in the study population.
Race/ethnicity modified the association between the two SNPs and breast cancer survival.
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Background
Epidemiologic evidence shows that folate deficiency is a
breast cancer risk factor [1,2]. MTHFR is a key enzyme in
the folate metabolism pathway and regulates the intracel-
lular folate pool for synthesis and methylation of DNA
[3,4]. Two common allele variants of the MTHFR gene
have been described, C677T (NCBI SNP ID: rs1801133)
and A1298C (rs1801131), that lead to amino acid substi-
tutions, Ala222Val and Glu429Ala, and to decreased
enzyme activity [5-7]. Heterozygous and homozygous car-
riers of the 677T allele variant have a 30–40% and 60–
70% reduced enzyme activity, respectively, as determined
by in vitro analysis of the MTHFR activity [5,7,8]. The
effect of the 1298C allele variant is less severe and
homozygous carriers of this allele have a more moderate
30–40% reduction of the enzyme activity, yet its function
remains controversial [6,7,9]. Furthermore, people who
are heterozygous at both loci, C677T and A1298C, experi-
ence an intermediate activity loss of 40–50% [6,7]. It has
been shown that the 677T variant increases the plasma
homocysteine concentration in humans and reduces DNA
methylation in cancer patients, which indicates a reduced
synthesis of methionine and a more limited availability of
the methyl donor, S-adenosyl-methionine, in the pres-
ence of the low activity T allele [5,10]. Many studies inves-
tigated the association between the two genotypes and
breast cancer incidence. Although significant associations
were observed in some studies, a clear linkage between
MTHFR  gene polymorphisms and the risk to develop
breast cancer has not been established [11-18].
Recently, the two MTHFR genotypes were found to mod-
ulate the chemosensitivity of cancer cells to 5-fluorouracil
and methotrexate [8,19]. Furthermore, the 677T variant
has been linked to severe toxicity during adjuvant treat-
ment of breast cancer with cyclophosphamide, meth-
otrexate, and 5-fluorouracil (CMF) [20]. Other reports
observed differing effects of the two genotypes on meth-
otrexate efficacy and toxicity in patients with rheumatoid
arthritis [21-23]. We hypothesized that the two SNPs may
affect outcome of breast cancer patients with surgery and
chemotherapy and studied the individual and combined
effects of the SNPs on breast cancer survival. Because the
tumor estrogen receptor-α (ER) status, race/ethnicity, and
alcohol consumption have been shown to influence the
metabolism of folate [1,2,17,24-28], we also examined
possible interactions between these factors and the two
MTHFR SNPs on breast cancer survival.
Methods
Study population
Breast cancer cases (n = 248) were women, who were
recruited between February of 1993 and August of 2003 in
the greater Baltimore area, as described previously [29].
All patients were identified through surgery lists and
enrolled into the study prior to surgery. They were selected
from a group of 361 breast cancer patients who were
recruited at the University of Maryland Medical Center,
the Baltimore Veterans Affairs Medical Center, Union
Memorial Hospital, Mercy Medical Center, and the Sinai
Hospital in Baltimore, Maryland. Selection was based on
eligibility criteria and the availability of survival informa-
tion. Cases were eligible if they had pathologically con-
firmed breast cancer, had residency in the greater
Baltimore area, were of African-American or Caucasian
descent by self-report, were diagnosed with breast cancer
within the last six months prior to recruitment, and had,
by self-report, no previous history of the disease. Patients
were excluded if they were HIV, HCV, or HBV carriers,
were IV-drug users, were institutionalized, or were physi-
cally or mentally unable to sign consent and complete the
questionnaire. All participants signed a consent form and
completed an interviewer-administered questionnaire.
The blood collection was performed at the subjects' con-
venience but mostly at the conclusion of the interview. Of
the patients that were eligible under the original protocol
and could be contacted by phone, 83% agreed to partici-
pate in the study. One eligible patient died prior to surgery
and is not included in the study population. Additional
information to determine the ER status, disease stage,
treatment, and survival was obtained from medical
records and pathology reports, the Social Security Death
Index, and the National Death Index. The Institutional
Review Boards at the participating institutions approved
the study.
Histology evaluation and genotyping
A pathologist reviewed each tumor specimen to confirm
the presence of tumor and the histology. Disease staging
was performed according to the tumor-node-metastasis
(TNM) system of the American Joint Committee on Can-
cer/the Union Internationale Contre le Cancer (AJCC/
UICC). The two germline MTHFR  SNPs, C677T and
A1298C, were genotyped at the NCI Genotyping Core
Facility (GCF), using the assay conditions described in the
SNP500Cancer database [30]. We genotyped genomic
DNA from fresh-frozen breast tissue (170 non-tumor tis-
sues and 28 tumors) and buffy coat (n = 50) of the 248
patients. All genotype assays contained negative and pos-
itive controls, and 10% blinded duplicates consisting of
patient samples. We successfully genotyped 98% of the
cases for both genotypes (n = 243) and had a 100% con-
cordance among blinded duplicates for the two assays. In
addition, we analyzed the MTHFR  C677T genotype of
microdissected normal tissue from 21 of those 28 bulk
tumor samples that were genotyped at the NCI GCF. The
MTHFR  genotype of these samples was determined by
direct sequencing. We had 100% concordance between
the C677T genotypes of the bulk tumor samples and the
non-tumor tissue from these samples. The observed geno-BMC Cancer 2006, 6:257 http://www.biomedcentral.com/1471-2407/6/257
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type frequencies for both SNPs were in Hardy-Weinberg
equilibrium in our case population, and for a matched
control population (n = 317). Genotype frequencies
among African-Americans and Caucasians were in agree-
ment with the frequency data for these race/ethnic groups
in the SNP500Cancer database [30].
Statistical analysis
Stata 7.0 (Stata Corp, College Station, TX) and SAS 8.0
(SAS Institute, Cary, NC) statistical softwares were used
for data analysis. All statistical tests were two-sided and an
association was considered statistically significant with p <
0.05. The Kaplan-Meier method and the log-rank test were
used for univariate survival analysis. The Cox Propor-
tional-Hazards regression was used for multivariate sur-
vival analysis to calculate adjusted hazard ratios. A
statistical test for interaction was performed in Stata to
determine if the effect of the two MTHFR genotypes on
breast cancer survival is modified by other factors. In the
analysis, an interaction on breast cancer survival was
coded as "xi: stcox i.Var1*Var2". The interaction term was
coded with MTHFR genotypes as Var1 and other factors
(e.g., race, alcohol, and smoking) as Var2. Var1 and Var2
were coded as binary variables. For this test, the result was
coded as zero (or referent) for the common MTHFR geno-
type (C/C for SNP677 and A/A for SNP1298) and one for
the variant genotype (C/T or T/T for SNP677; A/C or C/C
for SNP1298). Alcohol consumption was coded as "no/
yes" for this test with "no" as the referent indicating a con-
sumption of 12 or less alcoholic drinks in life at the time
of recruitment. Survival was determined for the period
from the date of hospital admission to the date of the last
completed search for death entries in the Social Security
Index (August 18, 2004). The median and mean follow-
up times for overall survival were 47 and 55 months,
respectively, with a range of 12 to 140 months for the fol-
low up time. A total of 59 out of the 248 patients in the
study (24%) died during this period. We obtained death
certificates of the deceased cases and censored all causes of
death that were not related to breast cancer, such as acci-
dents, violent crimes, stroke, heart attack, and liver cirrho-
sis, in our analysis. The cause of death was not related to
breast cancer for 5 patients.
Results
Study population and MTHFR genotype distribution
We studied the relationship between the MTHFR C677T
and A1298C genotypes and disease outcome of 248 unse-
lected breast cancer patients. The clinicopathological fea-
tures of the patients are shown in Table 1. Most women
were of African-American descent, and 132 patients
received chemotherapy. Among those, 15 patients
received a 5-fluorouracil/methotrexate-based therapy, 71
patients received a doxorubicin-based combination ther-
apy, and the remaining 46 patients received either other
agents or the exact treatment modality was not reported.
The genotype distribution of the patients is shown in
Table 2. The genotype frequencies for C677T and A1298C
were significantly different between African-American and
Caucasian women. We also observed a linkage between
the two genotypes in our population (Table 3) that was
consistent with published data [31,32]. None of the
patients was homozygous for both variant alleles, and
only two patients were homozygous for one variant allele
and heterozygous for the other variant allele.
Table 1: Features of the breast cancer cases1
Age at diagnosis (mean ± SD; n = 248) 55.0 ± 13.9
Body mass index (mean ± SD; n = 248) 29.1 ± 8.0
N (%)
Race/Ethnicity
African-American 143 (58)
Caucasian 105 (42)
Menopausal status at diagnosis
Pre-menopausal 64 (31)
Post-menopausal 141 (69)
Alcohol consumption
No 93 (41)
Yes 133 (59)
Survival
Alive 189 (76)
Deceased2 59 (24)
Tumor histology
Ductal 189 (76)
Lobular 34 (14)
Others 25 (10)
Node status
Negative 144 (63)
Positive 84 (37)
Stage at diagnosis (TNM)
≤ Stage I 66 (29)
Stage II 118 (52)
≥ Stage III 44 (19)
Chemotherapy
No 99 (43)
Yes3 132 (57)
Neoadjuvant therapy
No 178 (77)
Yes 53 (23)
Estrogen receptor-α
Negative 102 (41)
Positive 145 (59)
HER2/neu
Low to weak 154 (62)
Moderate to strong 93 (38)
1 Cases with missing information are not included. SD = standard 
deviation. Race/ethnicity is determined by self-identification. Pre-
menopausal: still having menstruation. Post-menopausal: 55 years or 
older, or stated change of life, or hysterectomy with both ovaries 
removed. Alcohol consumption: yes if > 12 drinks in life at time of 
recruitment. 2 For 5 patients, the cause of death was not breast cancer. 
3 Includes neoadjuvant therapyBMC Cancer 2006, 6:257 http://www.biomedcentral.com/1471-2407/6/257
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MTHFR genotypes and breast cancer survival
We first examined the individual effects of the two geno-
types on breast cancer survival assuming a dominant
effect of the variant allele. C677T was not significantly
associated with breast cancer survival in the unstratified
Cox regression analysis with adjustments for age at diag-
nosis, race, A1298C, body mass index (BMI), ER status,
TNM stage, and chemotherapy (Table 4). Stratification by
ER-status and race revealed that the T allele (C/T or T/T)
was protective in patients with an ER-negative tumor and
in African-American patients. The association with ER-
negative tumors was marginally statistically significant.
The relationship between C677T and ER-negative but not
ER-positive breast cancer was also seen in the Kaplan-
Meier survival analysis (Figure 1a,b). To examine the
independent effect of C677T, we repeated our analysis but
included only those patients who were homozygous A/A
at codon 1298 (n = 135, see Table 3). In this stratified
analysis, the variant T allele at codon 677 (C/T or T/T)
remained protective, albeit non-significantly, in patients
with an ER-negative tumor (HR = 0.3; 95% CI, 0.06–1.47;
n = 51) and in African-American patients (HR = 0.14; 95%
CI, 0.02–1.09; n = 87).
The second MTHFR genotype, A1298C, was significantly
associated with survival in the unstratified analysis (Table
5). In contrast to C677T, the variant allele (A/C or C/C)
increased the risk of poor outcome. A stratification by the
ER status showed that the variant C allele lead to an
increased risk of dying only among patients with an ER-
negative tumor, as shown in the Kaplan-Meier (Fig. 1c,d)
and multivariate Cox regression analyses (Table 5). The
variant C allele was also associated with a significantly
increased risk of poor outcome among Caucasians and
among patients, who did not receive chemotherapy
(Table 5). To examine the independent effect of A1298C,
we repeated our analysis but included only those patients
who were homozygous C/C at codon 677 (n = 163, see
Table 3). We found that the variant C allele at codon 1298
(A/C or C/C) remained a significant predictor of poor sur-
vival among ER-negative patients matched on the C677T
genotype (HR = 3.27; 95% CI, 1.27–8.46; n = 62).
We also modeled the survival analysis assuming an addi-
tive effect (homozygous wild-type, heterozygous,
homozygous variant) by C677T and A1298C. Again, we
found that 677T was associated with an increased survival
of patients who either had an ER-negative tumor (HR =
0.36; 95% CI, 0.13–1.02) or were African-Americans (HR
= 0.12; 95% CI, 0.02–0.92). 1298C was associated with a
decreased survival of patients with an ER-negative tumor
(HR = 2.26; 95% CI, 1.17–4.37), Caucasians (HR = 2.53;
95% CI, 0.95–6.71), and patients who did not receive
chemotherapy (HR = 2.74; 95% CI, 0.79–9.5). The results
are very similar to those obtained with the assumption of
a dominant effect by 1298C (Table 5). Thus, the additive
and dominant models support the same conclusions.
MTHFR diplotypes and breast cancer survival
Next, we studied the combined effect of the two SNPs after
categorizing the genotypes into low and high MTHFR
enzyme activity diplotypes based on the previously
reported effect of the two variants on MTHFR activity [6].
Patients were classified as carriers of a high activity diplo-
type (n = 143) if they either had the CC (677) and AA
(1298) or the CC (677) and AC (1298) genotype combi-
nations (see Table 3). The CC(677)AC(1298) diplotype
has 80–90% of the enzyme activity encoded by the
CC(677)AA(1298) diplotype. All other genotype combi-
nations were considered low activity diplotypes (n = 100)
with a predicted MTHFR activity of 30–70% of the
CC(677)AA(1298) diplotype. Carriers of a low activity
diplotype had a non-significantly increased survival in the
unstratified analysis and had a significantly increased sur-
vival if they were African-Americans (Table 6). Overall,
the observed hazard ratios for the diplotypes were similar
to the hazard ratios obtained for C677T but divergent
from the hazard ratios obtained for A1298C.
Table 3: Linkage between C677T and A1298C genotypes in the 
patient population
C677T
A1298C C/C C/T T/T Total
A/A 87 40 8 135
A/C 56 30 1 87
C/C 20 1 0 21
Total 163 71 9 243
Table 2: Distribution of C677T and A1298C genotypes by race/
ethnicity1
African-
American n (%)
Caucasian 
n (%)
p-value2 Combined n (%)
C677T
C/C 114 (81) 49 (48) < 0.001 163 (67)
C/T 27 (19) 44 (43) 71 (29)
T/T 0 9 (9) 9 (4)
A1298C
A/A 98 (69) 37 (36) < 0.001 135 (56)
A/C 38 (27) 49 (48) 87 (36)
C/C 5 (4) 16 (16) 21 (8)
1 Only cases who were successfully genotyped for both SNPs (n = 
243) are included
2 Chi-square test comparing genotype distributions between African-
Americans and CaucasiansBMC Cancer 2006, 6:257 http://www.biomedcentral.com/1471-2407/6/257
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Interaction analysis
Lastly, we examined interactions between the SNPs and
other risk factors on breast cancer survival. We did not
observe an interaction with the ER status and chemother-
apy. We found a significant protective interaction between
the variant C allele at codon 1298 (A/C or C/C) and alco-
hol consumption on breast cancer survival (A1298C, pinter-
action = 0.017). Patients who reported to consume alcohol
at recruitment had an improved survival, compared to
nondrinkers, if they carried the 1298C allele because of
the interaction. There was no such interaction with C677T
or the MTHFR diplotype (C677T, pinteraction = 0.43; MTHFR
diplotype, pinteraction = 0.64). We also observed interactions
between the two genotypes and race/ethnicity on breast
cancer survival (C677T, pinteraction = 0.026; A1298C, pinterac-
tion = 0.088; MTHFR diplotype, pinteraction = 0.054). Because
of the interaction, African-American women had
improved survival, compared to Caucasian women, if
they were carriers of either the variant T allele at codon
677 (C/T or T/T), the variant C allele at codon 1298 (A/C
or C/C), or the low activity MTHFR diplotype. The data
are consistent with the results of the Cox regression anal-
yses for C677T, A1298C, and the MTHFR diplotypes that
showed an increased survival hazard of Caucasian women
when compared with African-American women in the
stratified analyses (Tables 4 to 6).
Discussion
In our study of 248 African-American and Caucasian
women with incident breast cancer, the MTHFR gene pol-
ymorphisms, C677T and A1298C, were associated with
breast cancer survival. The effects were stronger in patients
with estrogen receptor-negative tumors. We also observed
an interaction between the two SNPs and race/ethnicity
on breast cancer survival. The interaction decreased the
survival hazard among African-American women and
increased the survival hazard among Caucasian women.
This finding indicates that race/ethnicity is an important
modifier of the effect that MTHFR  genotypes have on
breast cancer survival.
It is plausible that MTHFR gene polymorphisms influence
breast cancer survival. Folate is critical for DNA synthesis,
DNA repair and epigenetic regulation of transcription.
Folate deficiency causes uracil misincorporation into
human DNA and induces chromosome breakage, and it
has been argued that the protective effect of the 677T
allele in colon cancer is related to a decreased incorpora-
tion of uracil into DNA [33,34]. There is evidence that the
677T allele increases thymidylate synthase activity in can-
cer cells because of an increased supply of 5,10-methyl-
eneTHF, the methyl donor for methylation of dUMP to
dTMP [8]. This increase of dTMP synthesis may come at
the cost of a diminished global DNA methylation because
cancer patients with a 677T allele (C/T or T/T) have con-
stitutively low levels of 5-methylcytosine in their tumors
and surrounding normal tissue [10]. Animal experiments
support the notion that a low MTHFR activity leads to
decreased DNA methylation. Heterozygous and
homozygous  MTHFR  knockout mice have significantly
Table 4: MTHFR C677T and breast cancer survival
Person-years1 # events2 HR (95% CI)3 p-value
C677T genotype (n = 198)
C/C 1
C/T or T/T 873 46 0.65 (0.31–1.35) 0.25
ER-negative (n = 84)
C/C 1
C/T or T/T 352 29 0.36 (0.12–1.04) 0.06
ER-positive (n = 114)
C/C 1
C/T or T/T 521 17 1.12 (0.35–3.59) 0.82
African-American (n = 121)
C/C 1
C/T or T/T 520 29 0.12 (0.02–0.92) 0.04
Caucasian (n = 77)
C/C 1
C/T or T/T 352 17 1.89 (0.57–6.32) 0.3
No Chemotherapy (n = 81)
C/C 1
C/T or T/T 394 13 0.88 (0.21–3.74) 0.87
Chemotherapy (n = 117)
C/C 1
C/T or T/T 479 33 0.55 (0.22–1.34) 0.19
1 Time at risk in person-years. 2 Number of deaths due to breast cancer. 3 Cox Proportional-Hazards regression with adjustments for age at 
diagnosis, race, A1298C, BMI, estrogen receptor, TNM stage, and chemotherapy.BMC Cancer 2006, 6:257 http://www.biomedcentral.com/1471-2407/6/257
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lower S-adenosylmethione levels and global hypomethyl-
ation when compared to the MTHFR wild-type littermates
[35]. Distinct DNA hypermethylation profiles have been
associated with breast cancer and may lead to disease pro-
gression and metastasis [36]. However, MTHFR gene pol-
ymorphisms also affect the efficacy and toxicity of
chemotherapeutics [37]. Because the direction of the
effect is not uniform [19,20,38], and because intrinsic fac-
tors and lifestyle may further modify the effect of MTHFR
gene polymorphisms, it is difficult to predict how MTHFR
gene polymorphisms will influence cancer outcome.
There has been only one other study that examined the
effect of MTHFR genotypes on breast cancer survival, and
the authors did not observe a significant association
between the two SNPs and survival of breast cancer
patients from the Shanghai area in China [39]. Differences
between these results and our associations could be due to
Association between MTHFR genotypes and breast cancer survival after stratification by ER-status Figure 1
Association between MTHFR genotypes and breast cancer survival after stratification by ER-status. Shown are the Kaplan-
Meier survival curves. (a) Cumulative survival of ER-negative patients by C677T status (n = 101). The survival of patients who 
carry the variant C677T genotype (n = 30; C/T or T/T) is significantly better than the survival of patients with the common 
genotype (n = 71; C/C). Log-rank test: p = 0.04. (b) Cumulative survival of ER-positive patients by C677T status (n = 144). The 
survival of patients who carry the variant C677T genotype (n = 50) is not significantly different from the survival of patients 
with the common genotype (n = 94). Log-rank test: p = 0.95. (c) Cumulative survival of ER-negative patients by A1298C status 
(n = 101). The survival of patients who carry the variant A1298C genotype (n = 38; A/C or C/C) is significantly worse than the 
survival of patients with the variant genotype (n = 63; A/A). Log-rank test: p = 0.02. (d) Cumulative survival of ER-positive 
patients by A1298C status (n = 143). The survival of patients who carry the variant A1298C genotype (n = 70) is not signifi-
cantly different from the survival of patients with the common genotype (n = 73). Log-rank test: p = 0.68.
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Table 6: MTHFR diplotypes and breast cancer survival
HR (95% CI)1 p-value
MTHFR diplotypes (n = 198)2
CC/AA + CC/AC (high enzyme activity) 1
Others (low enzyme activity) 0.61 (0.3–1.22) 0.16
ER-negative (n = 84)
CC/AA + CC/AC 1
Others 0.47 (0.19–1.20) 0.11
ER-positive (n = 114)
CC/AA + CC/AC 1
Others C 0.83 (0.27–2.59) 0.75
African-American (n = 121)
CC/AA + CC/AC 1
Others 0.22 (0.05–0.96) 0.04
Caucasian (n = 77)
CC/AA + CC/AC 1
Others 1.19 (0.36–3.96) 0.78
No Chemotherapy (n = 81)
CC/AA + CC/AC 1
Others 0.54 (0.15–1.96) 0.35
Chemotherapy (n = 117)
CC/AA + CC/AC 1
Others 0.59 (0.25–1.38) 0.23
1 Cox Proportional-Hazards regression with adjustments for age at diagnosis, race, BMI, estrogen receptor, TNM stage, and chemotherapy. Time at 
risk and number of events for the strata are shown in Tables 4 and 5.
2 MTHFR diplotypes were generated from the C677T and A1298C genotypes using the information shown in Table 3. Diplotypes were 
dichotomized into a group that encodes a high activity enzyme [CC(677) and AA or AC(1298)] and a group that encodes a low activity enzyme (all 
other diplotypes).
Table 5: MTHFR A1298C and breast cancer survival
Person-years1 # events2 HR (95% CI)3 p-value
A1298C genotype (n = 198)
A/A 1
A/C or C/C 873 46 2.05 (1.05–4.00) 0.03
ER-negative (n = 84)
A/A 1
A/C or C/C 352 29 2.70 (1.17–6.23) 0.02
ER-positive (n = 114)
A/A 1
A/C or C/C 521 17 1.39 (0.43–4.48) 0.58
African-American (n = 121)
A/A 1
A/C or C/C 520 29 1.57 (0.70–3.56) 0.28
Caucasian (n = 77)
A/A 1
A/C or C/C 352 17 6.28 (1.25–31.7) 0.03
No Chemotherapy (n = 81)
A/A 1
A/C or C/C 394 13 7.50 (1.49–37.7) 0.01
Chemotherapy (n = 117)
A/A 1
A/C or C/C 479 33 1.62 (0.76–3.46) 0.21
1 Time at risk in person-years. 2 Number of deaths due to breast cancer. 3 Cox Proportional-Hazards regression with adjustments for age at 
diagnosis, race, C677T, BMI, estrogen receptor, TNM stage, and chemotherapy.BMC Cancer 2006, 6:257 http://www.biomedcentral.com/1471-2407/6/257
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examining different populations. Our study provided evi-
dence that the effect of MTHFR genotypes on breast cancer
survival differs by race/ethnicity. It is likely that the prev-
alence of factors that may influence the effect of MTHFR
genotypes on breast cancer survival, such as tumor ER sta-
tus, mode of therapy, or folate status, is different from
patient population to patient population. For example,
ER-negative tumors are more common among African-
American women than other race/ethnic groups and these
tumors are treated differently than ER-positive tumors
[40]. Most patients in the Shanghai Breast Cancer study
appear to have received 5-fluorouracil, a therapy that was
infrequent in our patient group. Race/ethnicity is also a
determinant of the folate status. African-Americans tend
to have a lower folate intake than other race/ethnic groups
and in a controlled trial, blood folate concentrations and
folate excretion varied by race/ethnicity although the die-
tary folate intake and the C677T genotype were the same
among all participants [26,27]. This observation that the
folate status is different by race/ethnicity in a population
matched on the C677T genotype (all C/C) and with iden-
tical folate intake may explain why we observed an inter-
action between race/ethnicity and the MTHFR genotypes
on breast cancer survival. Finally, it should be mentioned
that an ER-negative tumor status was a significant inde-
pendent predictor of poor outcome in our population but
it was not in the Shanghai Breast Cancer Study as judged
by the 5-year survival rate [39].
The finding that MTHFR genotypes are associated with
breast cancer survival depending on the tumor ER status is
novel. It has been observed that total folate intake is asso-
ciated with the incidence of breast cancer depending on
the tumor ER status. In the Nurses' Heath Study, a higher
folate intake was associated with a lower risk of ER-nega-
tive but not ER-positive breast cancer [17]. The authors
hypothesized that adequate folate intake may be prima-
rily important in preventing ER-negative tumors. ER-neg-
ative tumors may represent a distinct subtype of breast
cancer, as revealed by the gene expression patterns of
human breast tumors [41,42], and MTHFR may have a
more significant role in the development and progression
of this tumor type than ER-positive tumors. It is also pos-
sible that the estrogen receptor regulates the intracellular
folate metabolism, a function, which would be lost in ER-
negative tumors. There is support for this hypothesis. The
estrogen receptor has been shown to repress the expres-
sion of the folate receptor α, and an inverse correlation
between ER and folate receptor expression in breast cancer
has been reported [24,25]. The folate receptor α is overex-
pressed in many human malignancies and shuttles folate,
folate conjugates, and antifolate compounds into cells
[43].
We found an opposite effect by C677T and A1298C on
breast cancer survival although both variant alleles were
found to decrease MTHFR enzyme activity [5-7]. The 677T
variant allele increased survival among ER-negative
patients. The 1298C variant allele was associated with a
significantly decreased survival of ER-negative patients.
There is evidence that the two SNPs may have different
effects on the biochemical properties of MTHFR [9]. The
A1298C leads to a substitution of a glutamine by alanine
in the regulatory domain of the enzyme but does not
cause thermolability of the enzyme or enzyme instability
in the presence of low folate, like C677T [7,9]. Several
reports showed that the two SNPs have different effects on
the efficacy and toxicity of methotrexate and 5-fluorour-
acil. The 1298C variant allele was found to be associated
with fewer adverse effects and higher efficacy and the
677T variant allele with an increased systemic toxicity in
rheumatoid arthritis and cancer patients [20,21,23,38]. A
methotrexate/5-fluorouracil-based therapy, however, was
not a factor in our study. Most of the chemotherapy-
treated patients received a combination of adriamycin
and cyclophosphamide and only a few patients were
treated with methotrexate and/or 5-fluorouracil.
Other studies observed opposite effects by these two
SNPs. In the Long Island Breast Cancer Study, the 677T
variant allele was associated with an increased risk of
breast cancer and the 1298C variant allele was associated
with a decreased risk of breast cancer [15]. The authors
hypothesized that the inverse correlations were caused by
the linkage disequilibrium between C677T and A1298C
that links a low activity genotype at one locus to a high
activity genotype at the other locus [31,32]. Even though
we observed a linkage between the two SNPs in our study
population, it does not fully explain the opposite effects
of the two SNPs on survival. We performed additional
analyses where we controlled for the confounding effect
of the second MTHFR genotype. When we used this strat-
ified approach, the two SNPs still had the same opposite
effect on breast cancer survival. We further addressed the
relationship between survival and MTHFR genotypes by
categorizing patients into carriers of diplotypes that
encode a MTHFR enzyme with either a low or high activ-
ity, as estimated in vitro [6]. In this analysis, which exam-
ines the effect of MTHFR activity rather than genotypes,
the risk estimates for breast cancer survival were remarka-
bly similar for the low activity diplotype and the low activ-
ity 677T variant but different from 1298C suggesting that
the effect of C677T on survival mirrors the enzyme activity
loss while the effect of A1298C does not.
Our study has several limitations. The current sample size
did not allow us a more in-depth examination of the effect
of race/ethnicity in a stratified analysis and we performed
a number of subgroup analyses, which increases the pos-BMC Cancer 2006, 6:257 http://www.biomedcentral.com/1471-2407/6/257
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sibility of chance finding. The subgroup analyses
addressed hypotheses based on previous findings from
observational studies suggesting that the ER-status, race/
ethnicity, and chemotherapy could act as effect modifiers
of the MTHFR genotypes. These hypotheses were formu-
lated a priori, and our data that the ER-status and race/eth-
nicity modify the effect of MTHFR genotypes on survival
are consistent with previous observations and biologically
plausible. It is also a limitation that we could not include
the patients' folate status into our analysis. Blood folate
concentrations or a long-term assessment of the folate
intake were not available. Folate intake is associated with
the incidence of breast cancer and interactions between
folate and MTHFR genotypes in relation to breast cancer
risk have been observed in several epidemiological studies
[2,14,15,17]. Alcohol acts as a folate antagonist and is a
modifier of the risk association between folate and breast
cancer [2,17,28]. We observed a significant interaction
between A1298C and alcohol consumption on breast
cancer survival. This observation may suggest that the
folate status is a modifier of relationship between MTHFR
genotypes and breast cancer survival. There is one report
that examined the relationship between folate intake and
survival of breast cancer patients with chemotherapy [44].
In the study, the authors did not observe a significant
association between folate intake and breast cancer sur-
vival but the study did not examine MTHFR genotypes.
Conclusion
We found that two functional polymorphisms in the
MTHFR gene affect the survival of breast cancer patients
with ER-negative tumors. We did not observe significant
interactions between the two SNPs and chemotherapy on
breast cancer survival but observed interactions with race/
ethnicity and alcohol consumption.
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